L’hypnose comme alternative concrète De plus en plus de personnes s’interrogent sur la nécessité d’un traitement ...

La fonction de patient-expert apparaît fortement rattachée à l’émergence de l’éducation thérapeutique (ETP), qui selon l’Organisation mondiale de la Santé (OMS), « vise à aider les patients à acquérir ...

Même s’il demeure encore peu connu du grand public, le patient-expert est progressivement devenu un acteur-clé du système de santé français, autour des notions de prévention et d’éducation ...

During the first quarter of 2026, the Patient Opportunity Equity Strategy generated a total return of -5.96% net of fees. The portfolio ended the quarter with 36 holdings where the top 10 stocks ...

The FDA has set a PDUFA date of August 30, 2026, for ropeginterferon alfa-2b-njft's application in essential thrombocythemia. Phase 3 SURPASS-ET trial showed superior efficacy and safety of ...

INCA033989 targets mutCALR in ET patients with Type 1 CALR mutations, showing promise in early trials with rapid, durable hematological responses and a favorable safety profile. CALR mutations are ...

The FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...

A female doctor sits at her desk and examines a patient's ear with an otoscope . She is wearing a white coat and stethoscope and is looking into her ear . On the table in front of them is a pill ...

Patient safety sets the foundation for a safe, equitable, trustworthy care experience — regardless of whether you’re operating in a virtual health system or a physical one. And yet, despite increased ...